Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 7/2022

23-07-2021 | Autoimmune Pancreatitis | Original Article

Correlation of Autoimmune Pancreatitis and Malignancy: Systematic Review and Meta-Analysis

Authors: Hossein Haghbin, Justin Chuang, Rawish Fatima, Nuruddinkhodja Zakirkhodjaev, Wade Lee-Smith, Muhammad Aziz

Published in: Digestive Diseases and Sciences | Issue 7/2022

Login to get access

Abstract

Background

There is conflicting evidence regarding autoimmune pancreatitis (AIP) association with pancreatic and non-pancreatic cancers. Literature lacks data on overall prevalence of malignancies in autoimmune pancreatitis.

Aim

Given the lack of definite evidence, we aimed to pool and summarize data from available literature regarding prevalence of different malignancies in AIP.

Methods

We conducted a systematic search of MEDLINE, EMBASE, Cochrane Register of Controlled Trials, and Web of Science through February 16, 2021, to include observational studies assessing the incidence of cancer in AIP. We used the DerSimonian–Laird method with random effects for meta-analysis. Pooled prevalence, 95% confidence interval (CI), and I2 statistic are reported.

Results

A total of 17 studies with 2746 patients were included assessing the prevalence of cancer in AIP. The overall prevalence of cancer in AIP was 9.6% [95% confidence interval (CI), 5.7–13.5%]. The cancers with the highest prevalence in AIP population were gastric and colorectal cancer, with prevalence of 1.3% (95% CI, 0.5–2.1%) and 1.2% (95% CI, 0.6–1.8%), respectively.

Conclusion

We demonstrate the prevalence of different cancers in AIP. Inflammatory surge in AIP and subsequent carcinogenesis is one explanation for this association. Moreover, AIP can be a paraneoplastic syndrome manifestation of malignancies.
Appendix
Available only for authorised users
Literature
1.
Raina A, Yadav D, Krasinskas AM, McGrath KM, Khalid A, Sanders M et al. Evaluation and management of autoimmune pancreatitis: experience at a large US center. Am J Gastroenterol 2009;104:2295–2306.PubMedPubMedCentralCrossRef
2.
Hoffmanova I, Gurlich R, Janik V, Szabo A, Vernerova Z. Dilemmas in autoimmune pancreatitis. Surgical resection or not? Bratisl Lek Listy 2016;117:463–467.PubMed
3.
4.
Minaga K, Watanabe T, Hara A, Kamata K, Omoto S, Nakai A et al. Identification of serum IFN-α and IL-33 as novel biomarkers for type 1 autoimmune pancreatitis and IgG4-related disease. Sci Rep 2020;10:14879.PubMedPubMedCentralCrossRef
5.
6.
Chari ST, Takahashi N, Levy MJ, Smyrk TC, Clain JE, Pearson RK et al. A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. Clin Gastroenterol Hepatol 2009;7:1097–1103.PubMedCrossRef
7.
Okazaki K, Kawa S, Kamisawa T, Naruse S, Tanaka S, Nishimori I et al. Clinical diagnostic criteria of autoimmune pancreatitis: revised proposal. J Gastroenterol 2006;41:626–631.PubMedPubMedCentralCrossRef
8.
Kim KP, Kim MH, Kim JC, Lee SS, Seo DW, Lee SK. Diagnostic criteria for autoimmune chronic pancreatitis revisited. World J Gastroenterol 2006;12:2487–2496.PubMedPubMedCentralCrossRef
9.
Akshintala VS, Singh VK. Management of autoimmune pancreatitis. Clin Gastroenterol Hepatol 2019;17:1937–1939.PubMedCrossRef
10.
Hart PA, Kamisawa T, Brugge WR, Chung JB, Culver EL, Czakó L et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut 2013;62:1771–1776.PubMedCrossRef
11.
Okazaki K, Chari ST, Frulloni L, Lerch MM, Kamisawa T, Kawa S et al. International consensus for the treatment of autoimmune pancreatitis. Pancreatology 2017;17:1–6.PubMedCrossRef
12.
Masamune A, Nishimori I, Kikuta K, Tsuji I, Mizuno N, Iiyama T et al. Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis. Gut 2017;66:487–494.PubMedCrossRef
13.
Okamoto A, Watanabe T, Kamata K, Minaga K, Kudo M. Recent updates on the relationship between cancer and autoimmune pancreatitis. Intern Med (Tokyo, Japan) 2019;58:1533–1539.CrossRef
14.
Masamune A, Kikuta K, Hamada S, Tsuji I, Takeyama Y, Shimosegawa T et al. Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2016. J Gastroenterol 2020;55:462–470.PubMedCrossRef
15.
16.
17.
Deeks JJ, Dinnes J, Damico R, Sowden AJ, Sakarovitch C, Song F et al. Evaluating non-randomised intervention studies. Health Technol Assess 2003;7:1–173.CrossRef
18.
Buijs J, Cahen DL, van Heerde MJ, Rauws EA, de Buy Wenniger LJ, Hansen BE et al. The long-term impact of autoimmune pancreatitis on pancreatic function, quality of life, and life expectancy. Pancreas 2015;44:1065–1071.PubMedCrossRef
19.
Dickerson LD, Farooq A, Bano F, Kleeff J, Baron R, Raraty M et al. Differentiation of autoimmune pancreatitis from pancreatic cancer remains challenging. World J Surg 2019;43:1604–1611.PubMedCrossRef
20.
Gupta R, Khosroshahi A, Shinagare S, Fernandez C, Ferrone C, Lauwers GY et al. Does autoimmune pancreatitis increase the risk of pancreatic carcinoma?: A retrospective analysis of pancreatic resections. Pancreas 2013;42:506–510.PubMedCrossRef
21.
Hart PA, Law RJ, Dierkhising RA, Smyrk TC, Takahashi N, Chari ST. Risk of cancer in autoimmune pancreatitis: a case-control study and review of the literature. Pancreas 2014;43:417–421.PubMedCrossRef
22.
Huggett MT, Culver EL, Kumar M, Hurst JM, Rodriguez-Justo M, Chapman MH et al. Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort. Am J Gastroenterol 2014;109:1675–1683.PubMedPubMedCentralCrossRef
23.
Ikeura T, Miyoshi H, Uchida K, Fukui T, Shimatani M, Fukui Y et al. Relationship between autoimmune pancreatitis and pancreatic cancer: a single-center experience. Pancreatology 2014;14:373–379.PubMedCrossRef
24.
Ishikawa T, Kawashima H, Ohno E, Iida T, Suzuki H, Uetsuki K et al. Risks and characteristics of pancreatic cancer and pancreatic relapse in autoimmune pancreatitis patients. J Gastroenterol Hepatol 2020;35:2281–2288.PubMedCrossRef
25.
Lee HW, Moon S-H, Kim M-H, Cho DH, Jun JH, Nam K et al. Relapse rate and predictors of relapse in a large single center cohort of type 1 autoimmune pancreatitis: long-term follow-up results after steroid therapy with short-duration maintenance treatment. J Gastroenterol 2018;53:967–977.PubMedCrossRef
26.
Nishino T, Toki F, Oyama H, Shimizu K, Shiratori K. Long-term outcome of autoimmune pancreatitis after oral prednisolone therapy. Intern Med 2006;45:497–501.PubMedCrossRef
27.
Rana SS, Gupta R, Nada R, Gupta P, Basher R, Mittal BR et al. Clinical profile and treatment outcomes in autoimmune pancreatitis: a report from North India. Ann Gastroenterol 2018;31:506–512.PubMedPubMedCentral
28.
Schneider A, Hirth M, Münch M, Weiss C, Löhr JM, Ebert MP et al. Risk of cancer in patients with autoimmune pancreatitis: a single-center experience from Germany. Digestion 2017;95:172–180.PubMedCrossRef
29.
Shimizu S, Naitoh I, Nakazawa T, Hayashi K, Miyabe K, Kondo H et al. Correlation between long-term outcome and steroid therapy in type 1 autoimmune pancreatitis: relapse, malignancy and side effect of steroid. Scand J Gastroenterol 2015;50:1411–1418.PubMedCrossRef
30.
Shiokawa M, Kodama Y, Yoshimura K, Kawanami C, Mimura J, Yamashita Y et al. Risk of cancer in patients with autoimmune pancreatitis. Am J Gastroenterol 2013;108:610–617.PubMedCrossRef
31.
Takuma K, Kamisawa T, Anjiki H, Egawa N, Igarashi Y. Metachronous extrapancreatic lesions in autoimmune pancreatitis. Intern Med 2010;49:529–533.PubMedCrossRef
32.
Takahashi N, Ghazale AH, Smyrk TC, Mandrekar JN, Chari ST. Possible association between IgG4-associated systemic disease with or without autoimmune pancreatitis and non-Hodgkin lymphoma. Pancreas 2009;38:523–526.PubMedCrossRef
33.
Xiang P, Zhang X, Wang C, Lang Y, Xu L, Huang L et al. Pancreatic tumor in type 1 autoimmune pancreatitis: a diagnostic challenge. BMC Cancer 2019;19:814.PubMedPubMedCentralCrossRef
34.
35.
Stone JH, Khosroshahi A, Deshpande V, Chan JKC, Heathcote JG, Aalberse R et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum 2012;64:3061–3067.PubMedPubMedCentralCrossRef
36.
Ikeda R, Kurakami K, Ohta N, Suzuki T, Saito Y, Kusano Y et al. Malignancies in patients with IgG4-related diseases in head and neck regions. Tohoku J Exp Med 2019;249:285–290.PubMedCrossRef
37.
Chen L, Orr CE, Wang T. Prevalence of histological features resembling autoimmune pancreatitis in neoplastic pancreas resections. Histopathology 2020;77:673–677.PubMedCrossRef
38.
39.
40.
Inoue D, Yoshida K, Yoneda N, Ozaki K, Matsubara T, Nagai K et al. IgG4-related disease: dataset of 235 consecutive patients. Medicine (Baltimore) 2015;94:e680.CrossRef
41.
Lennon VA, Kryzer TJ, Griesmann GE, O’Suilleabhain PE, Windebank AJ, Woppmann A et al. Calcium-channel antibodies in the Lambert–Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995;332:1467–1474.PubMedCrossRef
42.
43.
Guilmette J, Nosé V. Paraneoplastic syndromes and other systemic disorders associated with neuroendocrine neoplasms. Semin Diagn Pathol 2019;36:229–239.PubMedCrossRef
44.
Puthenparambil J, Lechner K, Kornek G. Autoimmune hemolytic anemia as a paraneoplastic phenomenon in solid tumors: a critical analysis of 52 cases reported in the literature. Wien Klin Wochenschr 2010;122:229–236.PubMedCrossRef
45.
Shiokawa M, Kodama Y, Yoshimura K, Kawanami C, Mimura J, Yamashita Y et al. Risk of cancer in patients with autoimmune pancreatitis. Off J Am Coll Gastroenterol | ACG 2013;108:610.CrossRef
46.
Evoli A, Minisci C, Di Schino C, Marsili F, Punzi C, Batocchi AP et al. Thymoma in patients with MG: characteristics and long-term outcome. Neurology 2002;59:1844–1850.PubMedCrossRef
47.
Gregory K, Ioannis IA, Wouter WH, Ashley BG. Paraneoplastic syndromes secondary to neuroendocrine tumours. Endocrine-Relat Cancer 2010;17:R173–R193.CrossRef
48.
Korniluk A, Koper O, Kemona H, Dymicka-Piekarska V. From inflammation to cancer. Ir J Med Sci 2017;186:57–62.PubMedCrossRef
49.
Rasch S, Valantiene I, Mickevicius A, Beer S, Rosendahl J, Charnley RM et al. Chronic pancreatitis: Do serum biomarkers provide an association with an inflammageing phenotype? Pancreatology 2016;16:708–714.PubMedCrossRef
50.
Nishimori I, Kohsaki T, Onishi S, Shuin T, Kohsaki S, Ogawa Y et al. IgG4-related autoimmune prostatitis: two cases with or without autoimmune pancreatitis. Intern Med 2007;46:1983–1990.PubMedCrossRef
51.
Khandelwal A, Inoue D, Takahashi N. Autoimmune pancreatitis: an update. Abdom Radiol (NY) 2020;45:1359–1370.CrossRef
52.
53.
54.
Welty FK, Alfaddagh A, Elajami TK. Targeting inflammation in metabolic syndrome. Transl Res 2016;167:257–280.PubMedCrossRef
55.
Wynne K, Devereaux B, Dornhorst A. Diabetes of the exocrine pancreas. J Gastroenterol Hepatol 2019;34:346–354.PubMedCrossRef
56.
Amin MN, Hussain MS, Sarwar MS, Rahman Moghal MM, Das A, Hossain MZ et al. How the association between obesity and inflammation may lead to insulin resistance and cancer. Diabetes Metab Syndr 2019;13:1213–1224.PubMedCrossRef
57.
58.
Signoretti M, Roggiolani R, Stornello C, Delle Fave G, Capurso G. Gut microbiota and pancreatic diseases. Minerva Gastroenterol Dietol 2017;63:399–410.PubMed
59.
Hamada S, Masamune A, Nabeshima T, Shimosegawa T. Differences in gut microbiota profiles between autoimmune pancreatitis and chronic pancreatitis. Tohoku J Exp Med 2018;244:113–117.PubMedCrossRef
60.
Mohammed H, Varoni EM, Cochis A, Cordaro M, Gallenzi P, Patini R et al. Oral dysbiosis in pancreatic cancer and liver cirrhosis: a review of the literature. Biomedicines 2018;6:115.PubMedCentralCrossRef
61.
Agustí A, García-Pardo MP, López-Almela I, Campillo I, Maes M, Romaní-Pérez M et al. Interplay between the gut-brain axis. Obesity and cognitive function. Front Neurosci 2018;12:155.PubMedPubMedCentralCrossRef
62.
Shimosegawa T, Kanno A. Autoimmune pancreatitis in Japan: overview and perspective. J Gastroenterol 2009;44:503–517.PubMedCrossRef
63.
Umehara H, Okazaki K, Nakamura T, Satoh-Nakamura T, Nakajima A, Kawano M et al. Current approach to the diagnosis of IgG4-related disease—combination of comprehensive diagnostic and organ-specific criteria. Mod Rheumatol 2017;27:381–391.PubMedCrossRef
64.
Perugino CA, Liu H, Pillai S. Disease severity linked to increase in autoantibody diversity in IgG4‐related disease: response to Shiokawa et al. Arthritis & Rheumatology. 2020.
Metadata
Title
Correlation of Autoimmune Pancreatitis and Malignancy: Systematic Review and Meta-Analysis
Authors
Hossein Haghbin
Justin Chuang
Rawish Fatima
Nuruddinkhodja Zakirkhodjaev
Wade Lee-Smith
Muhammad Aziz
Publication date
23-07-2021
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 7/2022
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-07179-9

Other articles of this Issue 7/2022

Digestive Diseases and Sciences 7/2022 Go to the issue

Original Article

Patient-Reported Outcome and Clinical Scores Are Equally Accurate in Predicting Mucosal Healing in Ulcerative Colitis: A Prospective Study

Original Article

Safety and Efficacy of Vedolizumab Versus Tumor Necrosis Factor α Antagonists in an Elderly IBD Population: A Single Institution Retrospective Experience

Original Article

Real-World Effectiveness and Safety of Ustekinumab in Elderly Crohn’s Disease Patients

Correspondence

A Commentary on Intracystic Glucose Levels Appear Useful for Diagnosis of Pancreatic Cystic Lesions: A Systematic Review and Meta-Analysis

Original Article

Prevalence of Adenomas on Surveillance Colonoscopies for Patients with a History of Colonic Polyps of Unknown Histology

Image of the Month

Colitis Cystica Profunda: A Rare Mimicker of Colorectal Neoplasia

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits